Welcome to our dedicated page for Viridian Therapeutics, Inc.\DE SEC filings (Ticker: VRDN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Viridian Therapeutics, Inc.\DE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Viridian Therapeutics, Inc.\DE's regulatory disclosures and financial reporting.
Viridian Therapeutics, Inc. (VRDN) reported that its Chief Medical Officer, Radhika Tripuraneni, exercised a stock option for 40,000 shares of common stock on 2026-08-14 at an exercise price of $13.21 per share. The exercised option, which was fully vested, now shows 0 derivative shares remaining, and her directly held common stock position increased to 40,000 shares following the transaction.
Viridian Therapeutics, Inc. received an updated Schedule 13G/A reporting significant ownership by Paradigm BioCapital entities and Senai Asefaw, M.D. Paradigm BioCapital Advisors LP, its general partner, and Senai Asefaw each report beneficial ownership of 6,723,788 shares of Viridian common stock, representing 6.1% of the outstanding class as of the June 30, 2026 event date. Paradigm BioCapital International Fund Ltd. directly holds 5,896,154 shares, or 5.3% of the class. The ownership percentages are based on 110,427,682 shares outstanding as of May 11, 2026, following a Viridian common stock offering. The reporting parties state they have sole voting and dispositive power over their reported shares and disclaim beneficial ownership beyond shares directly held by each.
Kynam Capital Management, LP, its general partner Kynam Capital Management GP, LLC, and Yue Tang report their ownership in Viridian Therapeutics, Inc. common stock on an amended Schedule 13G. The group reports shared voting and dispositive power over 6,453,877 shares, representing 5.7% of the common stock. Each reporting person lists no sole voting or dispositive power and an aggregate amount beneficially owned of 0, while detailing the same shared voting and dispositive position. The securities are Viridian common stock, $0.01 par value, CUSIP 92790C104.
T. Rowe Price Associates, Inc. reported beneficial ownership of common stock of Viridian Therapeutics, Inc. as of June 30, 2026. The firm reported holding 5,748,426 shares of Viridian common stock, representing 5.2% of the class. T. Rowe Price Associates reported sole voting power over 5,748,380 shares and sole dispositive power over 5,748,426 shares, with no shared voting or dispositive power. The filing states that T. Rowe Price Associates denies beneficial ownership of the securities referenced.
Viridian Therapeutics, Inc. is reported to have 3,592,740 shares of its common stock beneficially owned by Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin in a joint filing. This position represents 3.25% of the company’s common stock, based on 110,427,682 shares outstanding as of May 8, 2026. All 3,592,740 shares are held with shared voting and dispositive power and no sole power, with ownership information stated as of June 30, 2026.
State Street Corporation reported a significant ownership position in Viridian Therapeutics, Inc.6,124,976 shares of Viridian common stock, representing 5.5% of the class.
All voting and dispositive authority over these shares is reported as shared, with 5,894,254 shares subject to shared voting power and 6,124,976 shares subject to shared dispositive power, and no shares under sole power. The position is held through subsidiaries including SSGA Funds Management, Inc. and several State Street Global Advisors entities.
Viridian Therapeutics is transitioning to a commercial-stage biopharma after U.S. approval of veligrotug, trade name Lumvoa, in June 2026 for thyroid eye disease. The company is also advancing elegrobart, a subcutaneous TED antibody, a thyroid stimulating hormone receptor program, and FcRn inhibitors VRDN-006 and VRDN-008.
For the three months ended June 30, 2026, total revenue was modest and primarily from license and collaboration fees, while research and development expense was $71,577 (in thousands) and selling, general and administrative expense was $54,975 (in thousands), leading to continued net losses. For the first half of 2026, the net loss reached $232,020 (in thousands), reflecting heavy investment in development and commercialization.
Liquidity remains strong, with $981.5 million in cash, cash equivalents and marketable securities as of June 30, 2026, which management expects to fund planned operations for at least twelve months. In 2026 the company issued $250.0 million of 1.75% convertible senior notes due 2032 and completed a $143.8 million common stock offering, then repaid its Hercules term loan. Non-dilutive funding includes a revenue participation arrangement with DRI that generated a $75.0 million milestone on veligrotug approval but carries a 27.4% effective interest rate and future U.S. sales-based royalties. Accumulated deficit was $1,570.5 million, underscoring reliance on external capital and eventual product uptake.
Viridian Therapeutics reported second-quarter 2026 results and significant milestones. Lumvoa (veligrotug-vvze) was approved by the FDA for thyroid eye disease on June 26, 2026, ahead of its target PDUFA date, and was immediately launched in the U.S. Elegrobart remains on track for a planned BLA submission in the first quarter of 2027, while FcRn and TSHR programs are expected to meet 2026 development milestones. The company also completed a May 2026 convertible debt and equity financing with gross proceeds of $394 million.
For the three months ended June 30, 2026, Viridian generated $284 thousand in total revenues and incurred $126,552 thousand of operating expenses, resulting in a net loss of $127,119 thousand, compared with $100,735 thousand a year earlier. Cash, cash equivalents, and marketable securities were $981,530 thousand as of June 30, 2026, supporting total assets of $1,097,233 thousand, liabilities of $435,136 thousand, and stockholders’ equity of $662,097 thousand.
Viridian Therapeutics director-associated funds received a new stock option grant linked to board service. Investment vehicles managed by Fairmount Funds Management LLC were granted an option covering 32,341 shares of Viridian common stock at an exercise price of $18.48 per share. The option vests in full on the earlier of July 1, 2027 or the company’s 2027 annual meeting of stockholders, if Christopher W. Cain continues serving on Viridian’s Board of Directors. The option expires on July 1, 2036. Under Cain’s arrangement with Fairmount, any net cash or stock from the option must be turned over to the adviser for the benefit of the Fairmount funds, and Cain disclaims beneficial ownership of both the option and the underlying shares.
Viridian Therapeutics director Jeffrey Robert Ajer received a grant of stock options for 32,341 shares of common stock at an exercise price of $18.48 per share. These options were awarded as compensation and give him the right to buy shares in the future at that fixed price. The options vest in full on the earlier of July 1, 2027 or the company’s 2027 annual meeting of stockholders, if he continues serving on the board until that time. After this grant, he holds stock options covering 32,341 underlying shares directly.